| Name | Title | Contact Details |
|---|---|---|
Elliott Walden |
Deputy General Counsel for Oversight | Profile |
HealthSherpas mission is to help every American feel the comfort and security of having health coverage. HealthSherpa is the largest and fastest-growing individual health coverage exchange in the United States, simplifying access to ACA and Medicare health plans from both federal and state marketplaces. Our secure, integrated technology platform empowers insurance agents, agencies, and carriers to quickly and accurately serve and support individuals as they select and use quality, affordable health plans.
Since our inception over a decade ago, the Undergraduate Investment Society (UIS) has maintained an unrivaled legacy as the premier business and finance organization at the University of California, San Diego. We train and empower members to the obtain financial literacy and business acumen needed to excel in various roles within the most competitive firms globally. We send more young professionals to Fortune 500 Companies and top tier investment banks like Goldman Sachs and Morgan Stanley, than all other campus organizations combined. We are proud to host the schools largest annual finance conference, the Financial Horizons Conference that, in the past 9 years, has seen an increase of professional, student, and alumni attendees. The Undergraduate Investment Society holds the highest standards for its committee members, meetings, and events to ensure that quality is consistent with the expansion of the organizations success. We continuously evolve by building bridges with corporations, community leaders, and other prominent figures within the financial world. Join the legacy.
Founded in 1999, YourCFOtoGo has provided services ranging from daily bookkeeping to executive-level advisory and consulting to clients in various industries. Although we have grown exponentially since our inception, our commitment to excellence is now and always will be the core of our business model.
Saber Law Group is women- and minority-owned boutique employment law and litigation firm based in San Francisco. * Saber attorneys hit the ground running with deep bench expertise and diverse backgrounds. * Saber attorneys are like legal, business, and operations strategists all in one. * Saber attorneys are driven by clients long-term success, many of whom have stayed with the team for decades. Our brand of client service is in high demand. Were expanding. How do you know youre ready to join Saber? * FOCUSED – You wont let anything stand in between yourself and your end goal. * INSPIRED – You are moved to practice law beyond a paycheck or a title. * RESILIENT – You have crossed hurdles and done anything to get to the finish line. * SOCIAL – You gather to share battle stories and wins at the finish line. * PREPARED – Youre an intricate planner, and preparation is vital for you. You dont just show up and hope for the best. When you turn up, you will be in prime condition. * BRAVE –The legal profession is one of the toughest. At Saber, you will be celebrated.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.